Antibiotic treatment choices for SBP Treviso 8 Giugno 2009 P. Angeli Dept. of Clinical and Experimental Medicine University of Padova.

Slides:



Advertisements
Similar presentations
Bacterial Infection in Liver Cirrhosis: the Microbiologist Point of View Prof. Marie-Hélène NICOLAS-CHANOINE.
Advertisements

TREATMENT FOR SUPERIMPOSED PSEUDOMONAS AERUGINOSA INFECTION.
Wes Theurer, DO.  Recognize sepsis early  Understand therapeutic principles  Cultures before antibiotics  Crystalloid fluid resuscitation  Antimicrobials.
The Resistance Problem PRSP = Penicillin Resistant Strep. pneumoniae QRSP = Quinolone Resistant Strep. pneumoniae MRSA = Methicillin Resistant Staph.
1 Benoît GUERY Infectious Diseases CHRU Lille Antibiotic strategies How to treat Multi-drug-resistant Pseudomonas.
Principles Of Antibiotics use Abdulrahman M. Al Mazrou, FRCPC Professor of Pediatrics,KSU Consultant, Pediatric Infectious diseases,KFMC Rajab-1431.
Choice of Antibiotics in Diverticulitis Jeff Poynter University of Michigan Medical School Jeff Poynter University of Michigan Medical School.
Prophylaxis antibiotics in colorectal surgery By: Hanaa Tashkandi.
Jennifer Ott, PharmD, BCPS Clinical Pharmacy Specialist, Infectious Diseases Eastern Maine Medical Center Bangor, ME
Community-acquired bacterial infections. The most frequent etiologic agents of bacterial tonsillitis and tonsillopharyngitis are Streptococcus pyogenes.
PHL 424 Antimicrobials 1 st Lecture By Abdelkader Ashour, Ph.D. Phone:
Should we change the recommendations related to antibiotic drug dosage/drug duration? Workshop on Economic Epidemiology Makerere University August, 2009.
Prof.Hanan Habib. To eradicate the offending organisms from the urinary bladder and tissues. The main treatment of UTI is by antibiotics.
CEPHALOSPORINS First used clinically in the early 1960’s. First used clinically in the early 1960’s. They have an important role in the modern treatment.
Use of antibiotics. Antibiotic use Antimicrobials are the 2 nd most common drugs prescribed by office based physicians In USA1992: 110 million oral antimicrobial.
Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 1 Improvement in Dose Selection: FDA Perspective IDSA/ISAP/FDA Workshop.
Antibiotic Monotherapy for Intraabdominal Infections IS BROAD SPECTRUM MONOTHERAPY ANTIBIOTIC TREATMENT ADEQUATE FOR INTRAABDOMINAL INFECTIONS ? Nicolas.
Optimizing Antibiotics Dr Samir Sahu. Time to Antimicrobial Therapy KHL.
Warren S. Joseph, DPM, FIDSA Roxborough Memorial Hospital, Phila., PA
CHOICE OF ANTIBIOTICS IN THE VIEW OF DEVELOPING ANTIBIOTIC RESISTANCE Dr. Jolanta Miciulevičienė Vilnius City Clinical Hospital National Public Health.
Multidrug-Resistant Bacteria in Solid Organ Transplantation Jordi Carratalà Department of Infectious Diseases IDIBELL-Hospital Universitari de Bellvitge.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 83 Basic Principles of Antimicrobial Therapy.
The Antibiotic Sensitivity Test Presented by Marian Mikhail Undergraduate student Biology Major Health and Science Concentration Health and Science Concentration.
1 Developed by Consensus III Medical Expert Group : Gert Höffken, Universitat Dresden, Dresden, Germany George Karam, Louisiana State University Medical.
Rational use of antibiotics in child infection
PRESENTER: HALIMATUL NADIA M HASHIM SUPERVISOR: DR NIK AZMAN NIK ADIB.
Adham Abu Taha, PhD Dept. of Pharmacology and Toxicology, College of Pharmacy, An-Najah National University, Nablus, Palestine Antimicrobial resistance.
Kh Sadique Faisal Asst. Lecturer Northern University Bangladesh.
Treatment of urinary tract infections Prof. Hanan Habib.
Aims of study This surveillance study was performed to determine the in vitro activity of ciprofloxacin against clinical isolates of Escherichia coli and.
Zunilda Djanun*, Rudyanto S**, Yulia Rosa***, *Dept. Clinical Pharmacology FMUI/CMH, **ICU CMH, *** Dept. Clinical Microbiology FMUI.
Life-Threatening Infections: Diagnosis and Antimicrobial Therapy Selection.
8th ISAP Symposium Can PK/PD be used in everyday clinical practice? Francesco Scaglione Department of Pharmacology, Toxicology and Chemotherapy, University.
Pharmacodynamics of Antimicrobials in Animal Models William A. Craig, M.D. University of Wisconsin-Madison.
Antimicrobial Resistance patterns among nosocomial gram negative bacilli by E-test and disc diffusion methods in Sina and Imam Hospital.
Systematic review + meta-analysis: 69 (quasi-)randomised trials: N=7,863 pts with sepsis: any BL monoTx vs any combination of BL + AG: N (studies) : same.
Spontaneous Bacterial Peritonitis Katherine Yu May 2014.
Hospital Acquired Pneumonia(HAP): is defined as a pneumonia which occurs after 48 hours of admission to hospital. Hospital Acquired Pneumonia(HAP): is.
Antimicrobial Resistance in Streptococcus pneumoniae Implications for Prescription Drug Labeling John H. Powers, MD Lead Medical Officer Antimicrobial.
Empirical Therapy for Ventilation Associated Pneumonia Azar. Hadadi Associate Professor of Infectious Diseases.
Pharmacodynamics of Antimicrobials in Animal Models William A. Craig, M.D. University of Wisconsin-Madison.
Center for Drug Evaluation and Research March 6, 2005 Bacteremia and Endocarditis: Products and Guidance Janice Soreth, MD Director Division of Anti-Infective.
Antimicrobials - Quinolones & Fluoroquinolones Antimicrobials - Quinolones & Fluoroquinolones Pharmacology -1 DSX 215 DSX 215 Dr/ Abdulaziz Saeedan Pharmacy.
PK/PD: TOWARDS DEFINITIVE CRITERIA PK/PD in clinical Practice: new level of PK/PD Francesco Scaglione Department of Pharmacology, Toxicology and Chemotherapy,
MICROBIOLOGICAL EPIDEMIOLOGY OF RESPIRATORY SPECIMENS IN ICU PATIENTS Dr Farooq Cheema, Dr Waseem Tariq, Dr Raja Ishtiaq, Dr Tabassum Qureshi, Dr Vincent.
Guideline for the Diagnosis and Management of Adults in LTC with Urinary Tract Infection (Part 2) This is intended as a guide for evidence-based decision-making.
Diamantis P. Kofteridis, Christina Alexopoulou, Antonios Valachis, Sofia Maraki, Dimitra Dimopoulou Clinical Infectious Diseases 2010; 51(11):1238–1244.
Tigecycline use in serious nosocomial infections: a drug use evaluation Matteo Bassetti*, Laura Nicolini, Ernestina Repetto, Elda Righi, Valerio Del Bono,
Multi-Resistant Gram Negative Microorganisms St Elisabeth Hospital Curacao.
1 A clinico-microbiological study of diabetic foot ulcers in an Indian tertiary care hospital DIABETES Care; Aug 2006; 29,8 : FM R1 임혜원.
PRINCIPLES OF ANTIBIOTIC THERAPY
Fungal Peritonitis (FP) Constantinos J. Stefanidis “P. and A. Kyriakou” Children’s Hospital Athens, Greece.
HAP and VAP Guidelines Update
Antibiotics: handle with care!
Management of Urinary Tract Infections Renal Block
Clinical Microbiology and Infection
Management of Urinary Tract Infections Renal Block
The aminoglycoside antibiotics
The Role of the Microbiology Laboratory in AMS programs
Antibiotics: handle with care!
Antibiotics sensitivity of microorganism causing nosocomial infections
The challenges of multi-drug-resistance in hepatology
Clinical Microbiology and Infection
G. Höffken  Clinical Microbiology and Infection 
Internal medicine L-4 Liver cirrhosis & portal hypertension
BY ABDULJALEEL ELSHALWI MAHMOUD ELMABRI ANTIBIOTICS PROTOCOLS IN A NEONATAL INTENSIVE CARE UNITE OF AL-WAHDA HOSPITAL DERNA.
Fluoroquinolone Nalidixic acid is the predecessor to all fluoroquinolones, a class of man-made antibiotics. Fluoroquinolones in use today typically offer.
Point prevalence survey (PPS) of healthcare associated infections (HAI) & antimicrobial use (AMU) in acute care Mark McConaghy, Dr Muhammad Sartaj,
Antibiotics: handle with care!
Presentation transcript:

Antibiotic treatment choices for SBP Treviso 8 Giugno 2009 P. Angeli Dept. of Clinical and Experimental Medicine University of Padova

Empirical antibiotic therapy must be initiated immediately after the diagnosis of the infection is made. Several antibiotics can be used for the initial therapy of SBP: cefotaxime or other third-generation cephalosporins, or amoxicillin-clavulanic acid or quinolones. The optimal cost- effective dosage has only been investigated for cefotaxime. For this antibiotic, a minimum dose of 2 g/12 hr i.v. should be administered in patients with normal renal function. In addition a minimum duration of 5 days of cefotaxime therapy is recommended. A. Rimola, et al. J. Hepatol ; 32 : Infections in cirrhosis Treatment of spontaneous bacterial peritonitis (SBP)

In 1990s cefotaxime or other third generation cephalosporins were investigated more extensively in the treatment of SBP on the basis of two factors: Gram negative aerobic bacteria from the family of Enterobacteriaceae were the most common causative microrganisms. A favourable pharmacokinetic property (i.e antibiotic concentration in the ascitic fluid > MIC 90 for causative microrganisms. Treatment of spontaneous bacterial peritonitis Infections in cirrhosis A. Rimola, et al. J. Hepatol ; 32 :

P < Prevalence of multiresistance to cefotaxime or amoxicillin/clavulanic acid in 224 patients with cirrhosis and bacterial infections Infections in cirrhosis (%) J.G. Acevedo et. al EASL Meeting P < 0.001P < 0.05P = N.S.

Main multiresistant bacteria isolated in 224 patients with cirrhosis and bacterial infections Infections in cirrhosis (number of cases) P < J.G. Acevedo et. al EASL Meeting

Risk factors for SBP due to extended-spectrum β-lactamase- producing Escherichia Coli and Klebsiella species (ESBL-EK) Infections in cirrhosis Risk factorESBL-EK (n=26) Non ESBl-EK (n=78) OR (95% CI) Hospital stay  2 weeks 13 (50%)3 (4%)35.11 (4.57 to ) Previous history of SBP 19 (73%)23 (30%)12.91 (2.88 to 57.96) Prior use of antibiotics within 30 days 21 (81%)13 (17%)15.13 (4.44 to 51.52) ICU care5 (19%)7 (9%)2.53 (0.70 to 9.12) Presentation of septic shock 11 (42%)22 (28%)2.21 (0.78 to 6.31) Kyoung-Ho Song et al. BMC Infect. Dis ; 9 : 41 (Epub ahead of print)

P < Resolution of bacterial infections with cefotaxime or amoxicillin/clavulanic acid in 224 patients with cirrhosis and bacterial infections Infections in cirrhosis (%) J.G. Acevedo et. al EASL Meeting P < P < 0.005P = 0.05

Mortality rate of spontaneous bacterial peritonitis and bacteremia by types of bacteria Infections in cirrhosis B. Campillo et al. Clin. Infect. Dis ; 35 : (%) P < 0.001

Infections in cirrhosis Resistances to antibiotic therapy in in 169 inpatients with cirrhosis and bacterial infections Preliminary unpublished data of an Italian multicenter study

Thirty day-mortality rate of spontaneous bacterial peritonitis by types of bacteria Infections in cirrhosis Kyoung-Ho Song et al. BMC Infect. Dis ; 9 : 41 (Epub ahead of print) 5 P < days SBP due to non ESBL-EK SBP due to ESBL-EK

A. Umgelter, et al. Infection 2009 ; (Epub ahead of print) Mortality in cirrhotic patients with ascites and SBP who failed to respond to the common first line therapies Infections in cirrhosis (%)(%) P < 0.001

Thirty day mortality in cirrhotic patients with SBP according to the efficacy of initial antibiotic therapy Infections in cirrhosis (%)(%) Kyoung-Ho Song et al. BMC Infect. Dis ; 9 : 41 (Epub ahead of print) P < 0.001

Treatment of nosocomial spontaneous bacterial peritonitis: proposal for consensus (1) Infections in cirrhosis Nosocomial bacterial infections including SBP are frequently caused by multiresistant bacteria in patients with cirrhosis. Third generation cephalosporins or amoxicillin-clavulanic acid are uneffective in a high percent of these patients and should not be used longer as first line empiric antibiotic treatment. A more effective empirical antibiotic therapy in these patients should include a combination of antibiotics with a broader spectrum such as carbapenems and glycopeptides or lipopeptides. In order to establish the best empirical antibiotic treatment of nosocomial infections in patients with cirrhosis further large multicenter studies are needed. De-escalation of the initially broad antimicrobial regimen should be undertaken only once definitive culture results are available.

Factors in the selection of antibiotics for enpirical therapy Infections in cirrhosis Expected antimicrobial susceptibility of infecting bacteria Potential risk to induce/select resistant bacteria Overall safety of the agents Their penetration in the site of infection Detrimental interactions with other drugs Costs

Pharmacokinetics and pahrmacodynamics of carbapenemes in peritoneal fluid Infections in cirrhosis K. Ikawa, et al. J. Infect. Chemother ; 14 :

Pharmacokinetics of teicoplanin in patients udergoing continuous ambulatory peritoneal dialysis Infections in cirrhosis D. Stamadiatis, et al. Perit. Dial. Int ; 23 :

Pharmacokinetics of daptomycin in patients udergoing continuous ambulatory peritoneal dialysis Infections in cirrhosis D. Stamadiatis, et al. Perit. Dial. Int ; 23 :

Failure of antibiotic treatment of spontaneous bacterial peritonitis (SBP) P. Angeli, et al. Aliment. Pharmacol. Ther ; 23 : FAILUREI.V. CEFTAZIDIME (n°=55) Switch therapy with CIPROFLOXACIN (n°=61) P No positive response9.09%11.47%N.S. Adverse effects1.82%3.28%N.S. Recurrence of infection 1.82%3.28%N.S. Superinfections3.64%1.64%N.S. TOTAL16.36%19.67%N.S. Infections in cirrhosis

Mean cost of treatment per patient with spontaneous bacterial peritonitis P. Angeli, et al. Aliment. Pharmacol. Ther ; 23 : Infections in cirrhosis * = P < * * * (€)(€)

Microrganisms E.Coli Pseudomonas sp. Klebsiella sp. EnterococciStaph aureus ESBL-producers17- 4 Resistance34 (76 %)2 (66%) 4 (57%) 18 (66%)5 (71%) Quinolones Cephalosporins Carbapenems Meticillin- -5 Vancomicina 1- Preliminary unpublished data of an Italian multicenter study Main multiresistant bacteria isolated in 169 inpatients with cirrhosis and bacterial infections Infections in cirrhosis

P < Resolution of bacterial infections with cefotaxime or amoxicillin/clavulanic acid in 224 patients with cirrhosis and bacterial infections Infections in cirrhosis (%) J.G. Acevedo et. al EASL Meeting P < P < 0.005P = 0.05

Geographic distribution of Escherichia Coli strains with a reduced susceptibility to ciprofloxacin in community-acquired UTI in Europe Infections in cirrhosis S. Cagnacci et al. J. Clin. Microb ; 46 :

Treatment of community-acquired spontaneous bacterial peritonitis (SBP): proposal for consensus (2) Infections in cirrhosis Up to now, third generation cephalosporins or amoxicillin-clavulanic acid can still be considered as the first-line empirical antibiotic therapy in patients with cirrhosis and community-acquired SBP. Quinolones may still be an alternative antibiotic choice in community- acquired SBP but only in patients who are not on prophylaxis with norfloxacin and only in countries with low prevalence of quinolone- resistance E. coli.